A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
概览
- 阶段
- 3 期
- 干预措施
- Darolutamide 300 mg
- 疾病 / 适应症
- Prostate Cancer Metastatic
- 发起方
- UNICANCER
- 入组人数
- 300
- 试验地点
- 170
- 主要终点
- Radiographic progression-free survival
- 状态
- 招募中
- 最后更新
- 4天前
概览
简要总结
This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors.
详细描述
This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors. The study plans to enroll 300 patients who will be randomized (1:1) to receive either: (i) Experimental arm: ADT + darolutamide 600 mg po bid, or (ii) Control arm: ADT + placebo po bid. Response to treatment will be assessed according to the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (Scher, 2016). Treatment will be continued until radiographic disease progression. Treatment may also be terminated at the initiative of either the patient or the investigator for any reason that would be beneficial to the patient, including: unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient request. Following treatment discontinuation patients will enter the follow-up period and will be monitored for up to 10 years with regards to survival status, subsequent antineoplastic treatments and the status of ongoing adverse events (AEs) and/or new investigational product related AEs.
研究者
入排标准
入选标准
- •Signed a written informed consent form prior to any trial specific procedures.
- •Men with histologically or cytologically confirmed adenocarcinoma of the prostate.
- •Aged ≥18 years old at the time of signing informed consent.
- •De novo metastatic disease defined by clinical or radiological evidence of metastases.
- •Note: For patients with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes (lymph nodes located above the iliac bifurcation) can be included if they have either:
- •At least one extra-pelvic lymph node ≥2 cm
- •At least one extra-pelvic lymph node ≥1 cm if the patients also have at least one pelvic lymph node ≥2 cm
- •Measurable disease or bone lesions that are evaluable according to PCWG3 criteria.
- •Ineligible for treatment with all of the following drugs: docetaxel, abiraterone, enzalutamide, apalutamide; AND meets at least one of the following frailty criteria:
- •Activities of daily living (ADL) assessment (excluding urinary incontinence question) score 3 or 4/5, or;
排除标准
- •Three or more Grade 3, or any Grade 4 events on the CISR-G questionnaire. Nota Bene: (Regarding CISR-G assessment, more specifically genitourinary scoring, score N°4 is not applicable).
- •Eastern Cooperative Oncology Group (ECOG) performance status score ≥
- •Hypertension not controlled by an anti-hypertensive treatment (systolic blood pressure \[BP\] ≥160 mmHg or diastolic BP ≥95 mmHg; 3 consecutive measures taken 5 minutes apart).
- •Acute toxicities of prior treatments and procedures not resolved to grade ≤1 or baseline before randomisation, with the exception of hot flushes and erectile dysfunction.
- •Previous systemic treatment for prostate cancer, except less than 12 weeks of ADT and/or an old-generation AR inhibitor.
- •Severe or uncontrolled concurrent disease, infection or co-morbidity.
- •Known hypersensitivity to the study treatment or any of its ingredients.
- •Major surgery within 28 days before randomisation.
- •Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV.
- •Prior malignancy ≤3 years before study enrolment. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any localized cancer for which treatment has been completed ≥6 months before randomisation and from which the subject has been disease-free, or for which the risk of relapse is less than 30%, as well as early stage chronic lymphocytic leukaemia that does not require any specific treatment.
研究组 & 干预措施
ADT + darolutamide
ADT + darolutamide 600 mg po bid
干预措施: Darolutamide 300 mg
ADT + darolutamide
ADT + darolutamide 600 mg po bid
干预措施: Androgen deprivation therapy
ADT + placebo
ADT + placebo po bid
干预措施: Placebo
ADT + placebo
ADT + placebo po bid
干预措施: Androgen deprivation therapy
结局指标
主要结局
Radiographic progression-free survival
时间窗: From randomisation to radiographic progression or death, up to 18 months
Time from randomisation to radiographic progression according to the Prostate Cancer Working Group 3 (PCWG3) criteria or death, whichever occurs first
次要结局
- Castration-resistant prostate cancer-free survival(From randomisation to onset of CRPC or death, up to 18 months)
- Clinical progression-free survival(From randomisation to clinical progression or death, up to 18 months)
- Frequency and severity of adverse events(From inclusion until 100 days after last dose of investigational product)
- Time to next symptomatic skeletal event(From randomisation to occurence of a skeletal event, up to 18 months)
- Second line radiographic progression-free survival(From randomization up to 10 years.)
- Progression-free survival after next line of treatment (PFS2)(From randomization up to 10 years.)
- Geriatric status(At baseline and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year)
- Overall survival(From randomization to death from any cause, up to 10 years.)
- Prostate cancer-specific survival(From randomization to death from prostate cancer, up to 10 years.)
- Health related quality of life questionnaire Brief Pain Inventory - Short Form (BPI-SF)(On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year)
- Time to worsening in prostate cancer-related urinary symptoms(On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year)
- Complete prostate specific antigen (PSA) response(At 6 months)
- Time to first subsequent systemic anti-cancer therapy (SACT)(From randomization up to 10 years.)
- Second line overall survival(From randomization up to 10 years.)
- Time to deterioration for EORTC QLQ-PR25 symptom subscales(On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year)
- Health related quality of life questionnaire EORTC-QLQ-PR25(On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year)
- Health related quality of life questionnaire EORTC-QLQ-C30(On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year)